58662-84-3
58662-84-3
Chemical Structure
Meclonazepam
Synonym(s): Ro 11-3128; Ro 11-3128/002
- CAS No.: 58662-84-3
- Formula:C16H12ClN3O3
- Molecular Weight:329.74
IUPAC Name: (S)-5-(2-chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one
InChIKey: LMUVYJCAFWGNSY-VIFPVBQESA-N
SMILES: O=C1NC2=CC=C([N+]([O-])=O)C=C2C(C3=CC=CC=C3Cl)=N[C@H]1C
Biological Activity: Meclonazepam (Ro 11-3128) is a benzodiazepine compound with anxiolytic effect[1]. Meclonazepam is active against immature S. mansoni. Meclonazepam (30 μM) eliminates 100% of immature parasites. Meclonazepam has a anti-schistosomal effect[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Meclonazepam | 99.97% | Meclonazepam (Ro 11-3128) is a benzodiazepine compound with anxiolytic effect. Meclonazepam is active against immature S. mansoni. Meclonazepam (30 μM) eliminates 100% of immature parasites. Meclonazepam has a anti-schistosomal effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Meclonazepam (Standard) | ≥98% | Meclonazepam (Standard) (Ro 11-3128 (Standard)) is the analytical standard of Meclonazepam (HY-101725). This product is intended for research and analytical applications. Meclonazepam (Ro 11-3128) is a benzodiazepine compound with anxiolytic effect. Meclonazepam is active against immature S. mansoni. Meclonazepam (30 μM) eliminates 100% of immature parasites. Meclonazepam has a anti-schistosomal effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. T U Järbe, et al. Cueing effects of anxiolytic benzodiazepines (DZP and Ro 11-3128): stereospecificity and antagonism by the convulsant benzodiazepine Ro 5-3663. Psychopharmacology (Berl). 1988;94(4):501-6. [Content Brief]
- [2]. L Pica-Mattoccia, et al. Praziquantel and the benzodiazepine Ro 11-3128 do not compete for the same binding sites in schistosomes. Parasitology. 2008 Jan;135(Pt 1):47-54. [Content Brief]
